Novacta Therapeutics and O2h Announce a Multi FTE Medicinal Chemistry Collaboration
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Novacta Therapeutics and O2h announced a multi FTE chemistry collaboration to support their internal drug discovery efforts. This is the third successive collaboration over the last three years.
“Following two very successful projects, we are excited to enter a third collaboration that combines the strengths of both companies.” said Dr. Sjoerd Wadman, Head of Chemistry at Novacta Therapeutics.
Sunil Shah, CEO of O2h said “We are excited to be a part of and support the research programs that Novacta is pioneering in the area of Lantibiotics and Bacteriocins. The large investment that they have received to date is testament to the scientific breakthroughs that they have made in this area”.
“Following two very successful projects, we are excited to enter a third collaboration that combines the strengths of both companies.” said Dr. Sjoerd Wadman, Head of Chemistry at Novacta Therapeutics.
Sunil Shah, CEO of O2h said “We are excited to be a part of and support the research programs that Novacta is pioneering in the area of Lantibiotics and Bacteriocins. The large investment that they have received to date is testament to the scientific breakthroughs that they have made in this area”.
